Structural Biology: The Atomic Spyglass Revolutionizing Medicine

σε πρόσθεσε στο Health

2026-07-29 09:56:34 -

For decades, KRAS was considered one of oncology’s most difficult drug targets. In 2013, crystallographic studies revealed a previously unrecognized pocket beneath the switch-II region of KRAS G12C, providing a structural basis for mutant-selective inhibitor design. Years of medicinal chemistry and clinical development followed, culminating in the first FDA approval of a KRAS G12C...

0 Σχόλια 0 Μοιράστηκε 55 Views 0 Προεπισκόπηση